Bloom Burton Has Bearish Forecast for TSE:MDP Q4 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Bloom Burton lowered their Q4 2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Bloom Burton analyst D. Martin now expects that the company will earn ($0.01) per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Other equities analysts have also issued research reports about the stock. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Stifel Nicolaus lifted their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. One research analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Up 10.1 %

Shares of TSE MDP opened at C$4.92 on Friday. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$5.56. The company has a market cap of C$120.69 million, a P/E ratio of 98.40 and a beta of 1.96. The business’s 50 day moving average is C$3.25 and its two-hundred day moving average is C$2.72.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.